5. Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. (2006)106(7):1569-80. 6. Dunleavy...
[7] Friis AM, Gyllensten K, Aleman A,et al.The Effect of Antiretroviral Combination Treatment on Epstein-Barr Virus (EBV) Genome Load in HIV-Infected Patients[J].Viruses,2010,2(4):867-879. [8] Diamantopoulos PT,Polonyfi K,Sofotasiou M,et al.Rit...
Her EBV protocol led to “the dramatic improvement and successful reversal of all symptoms in this disease for a rapid return 24-48 hours to optimal health.” She was able to “reduce the viral infection load including reversing splenomegaly within hours with (our) treatment from research on th...
[3] 中华医学会儿科学分会感染学组, 全国儿童EB病毒感染协作组. 儿童EB病毒感染相关疾病的诊断和治疗原则专家共识[J]. 中华儿科杂志, 2021,59(11):905-911. [4] Henter JI, Aricò M, Egeler RM, et al. 94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH study Group of the Histioc...
Treatment of EBV driven lymphoproliferation with erythrophagocytosis:12 year follow up[J].Journal of Clinical Pathology,2001.328.doi:10.1136/jcp.54.4.328.Bethune CA,GompelsMM,Taylor C,et al.Treatm ent of EBV driv-en lymphoproliferation w ith erythrophagocytosis:12 year follow up.Journal of C ...
2023年10月数据的更新分析显示tab-cel实现了49%的客观缓解率。此外，欧洲多中心扩大准入计划研究的真实世界结果显示，24名患者的客观缓解率为66.7%，并在2023年美国临床肿瘤学会年会上公布。参考来源：‘Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of ...
参考来源:‘Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA’,新闻稿。2024年5月20日发布。 注:本文旨在介绍医药健康研究,不作任何用药依据,具体用药指导...
Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease. Retrieved July 17, 2024....
Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA. Retrieved May 20, 2024. 注:以上资讯来源于网络,由香港济民药业整理编辑(如有错漏,请帮忙指正),只为提供全球最新...
Juarez-Vignon Whaley JJ, Afkhami M, Onyshchenko M, Massarelli E, Sampath S, Amini A, Bell D, Villaflor VM. Recurrent/Metastatic Nasopharyngeal Carcinoma Treatment from Present to Future: Where Are We and Where Are We Heading? Curr Treat Options Oncol. 2023 Sep;24(9):1138-1166. doi: 10...